Advanced search

Report side effect

Report a suspected side effect or falsified product to the MHRA Yellow Card scheme.
Go to {yellow_card_logo} site
{arrow_up} Back to top

Fludroxycortide 0.0125% w/w Cream

Active Ingredient:
Typharm Limited See contact details
ATC code: 
About Medicine
{healthcare_pro_orange} This information is for use by healthcare professionals
Last updated on emc: 19 Feb 2024
1. Name of the medicinal product

Haelan 0.0125% w/w Cream

Fludroxycortide 0.0125% w/w Cream

2. Qualitative and quantitative composition

Fludroxycortide 0.0125% w/w.

Excipients with known effect

Cetyl alcohol and propylene glycol

For the full list of excipients, see section 6.1.

3. Pharmaceutical form

Cream for topical administration.

4. Clinical particulars
4.1 Therapeutic indications

Adults and children: Eczema and dermatitis of all types including childhood and adult atopic eczema, photodermatitis, primary irritant and allergic dermatitis, lichen planus, lichen simplex, prurigo nodularis, discoid lupus erythematosus, necrobiosis lipoidica, pretibial myxoedema and erthroderma.

4.2 Posology and method of administration


For moist, weeping lesions, the cream should be applied gently to the affected area two or three times daily.

Method of administration

The elderly: As the skin is likely to be thin, apply sparingly to avoid development of atrophy.

Dilution is not recommended, but if considered necessary, aqueous cream BP may be used.

4.3 Contraindications

Tuberculosis of the skin, facial rosacea, acne vulgaris, perioral dermatitis, perianal and genital pruritus, dermatoses in infancy including eczema, dermatitic napkin eruption, bacterial (impetigo), viral (herpes simplex) and fungal (candida or dermatophyte) infections.

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

4.4 Special warnings and precautions for use

Preparations of Haelan are not intended for ophthalmic use.

Local and systemic toxicity is common especially following long-term continuous use, continued use on large areas of damaged skin, flexures and with polythene occlusion.

Systemic absorption of topical corticosteroids has produced reversible hypothalamic-pituitary-adrenal (HPA) axis suppression (see section 4.8). Therefore, patients receiving a large dose of a potent topical steroid applied to a large surface area or under an occlusive dressing should be evaluated periodically for evidence of HPA axis suppression by using urinary-free cortisol and ACTH stimulation tests. If HPA axis suppression is noted, an attempt should be made to withdraw the drug, to reduce the frequency of application or to substitute a less potent steroid. Recovery of HPA axis function is generally prompt and complete on discontinuation of the drug. Infrequently, signs and symptoms of steroid withdrawal may occur, so that supplemental systemic corticosteroids are required.

Long-term continuous therapy should be avoided in all patients irrespective of age.

Application under occlusion should be restricted to dermatoses in very limited areas.

If used on the face, courses should be limited to five days and occlusion should not be used.

In the presence of skin infections, the use of an appropriate antifungal or antibacterial agent should be instituted. If a favourable response does not occur promptly, Fludroxycortide should be discontinued until the infection has been adequately controlled.

Cetyl alcohol may cause local skin reactions (e.g. contact dermatitis).

Propylene glycol may cause skin irritation.

Instruct patients not to smoke or go near naked flames – risk of severe burns. Fabric (clothing, bedding, dressings etc) that has been in contact with this product burns more easily and is a serious fire hazard. Washing clothing and bedding may reduce product build-up but not totally remove it.

Topical steroid withdrawal syndrome

Long term use of topical steroids can result in the development of rebound flares after stopping treatment (topical steroid withdrawal syndrome). A severe form of rebound flare can develop which takes the form of a dermatitis with intense redness, stinging and burning that can spread beyond the initial treatment area. It is more likely to occur when delicate skin sites such as the face and flexures are treated. Should there be a reoccurrence of the condition within days to weeks after successful treatment a withdrawal reaction should be suspected. Reapplication should be with caution and specialist advise is recommended in these cases or other treatment options should be considered.

The label will state strong steroid.

Paediatric population

Usage in children: If used in children, courses should be limited to five days and occlusion should not be used.

Children may absorb proportionally larger amounts of topical corticosteroids and thus may be more susceptible to systemic toxicity. Children may also demonstrate greater susceptibility to topical corticosteroid induced HPA axis suppression and Cushing's Syndrome than do mature patients because a larger skin surface to body weight ratio. Administration of topical corticosteroids to children should be limited to the least amount compatible with an effective therapeutic regimen. Chronic corticosteroid therapy may interfere with the growth and development of children.

As with all topical steroids, the activity can be enhanced by the use of occlusive dressings. Preparations of Haelan are recommended only as a supplement to, and not as a substitute for, preparations (lotions, wet dressings etc.) used in the conventional management of skin lesions. Haelan Cream does not contain parahydroxybenzoates or lanolin.

4.5 Interaction with other medicinal products and other forms of interaction

Not known.

4.6 Fertility, pregnancy and lactation


There is an inadequate evidence of safety in human pregnancy. There may be a very small risk of cleft palate and intra-uterine growth retardation as well as suppression of the neonatal HPA axis. There is evidence of harmful effects in animals.

Use in pregnancy only when there is no safer alternative and when the disease itself carries risks for mother and child.


It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in the breast milk of nursing mothers. Systemically administered corticosteroids are secreted into the breast milk in quantities not likely to have a deleterious effect on the infant. Nevertheless, caution should be exercised when topical corticosteroids are administered to nursing mothers.

4.7 Effects on ability to drive and use machines

Not applicable.

4.8 Undesirable effects

The following local adverse reactions are reported infrequently with topical corticosteroids but may occur more frequently with the use of occlusive dressings. These reactions are listed in an approximate decreasing order of occurrence; burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, miliaria, striae and thinning and dilatations of the superficial blood vessels producing telangiectasia.

Prolonged use of large doses to extensive areas can result in sufficient systemic absorption to produce generalised manifestations of steroid toxicity and may result in depression of HPA function on discontinuing treatment.

Manifestations of Cushing's syndrome, hyperglycaemia and glycosuria have occurred in some patients.

Manifestations of adrenal suppression in children include linear growth retardation, delayed weight gain, low plasma cortisol levels and absence of response to ACTH stimulation. Intracranial hypertension including bulging fontanelles, headaches and bilateral papilloedema have also been reported in children receiving topical corticosteroids.

Infected skin lesions, viral, bacterial or fungal may be substantially exacerbated by topical steroid therapy. Wound healing is significantly retarded.

Hypersensitivity reactions may occur.

Skin and Subcutaneous Tissue Disorders Not known (cannot be estimated from available data)

Withdrawal reactions - redness of the skin which may extend to areas beyond the initial affected area, burning or stinging sensation, itch, skin peeling, oozing pustules. (see section 4.4)

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: or search for MHRA Yellow Card Scheme in the Google Play or Apple App Store.

4.9 Overdose

Topically applied corticosteroids can be absorbed in sufficient amounts to produce systemic effects. (See section 4.4).

5. Pharmacological properties
5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Corticosteroids, potent (group III), dermatological preparations, ATC code: D07AC07

Fludroxycortide is a fluorinated, synthetic, potent corticosteroid.

As with other topical steroids, the therapeutic effect is primarily the result of its anti-inflammatory, anti-mitotic and anti-synthetic activities.

5.2 Pharmacokinetic properties

Fludroxycortide applied under occlusive dressing has shown therapeutic improvement without disturbance of electrolyte, liver or renal function or suppression of adrenal function.

5.3 Preclinical safety data

There are no preclinical data of relevance to the prescriber in addition to that summarised in other sections of the Summary of Product Characteristics.

6. Pharmaceutical particulars
6.1 List of excipients

Stearic acid

Cetyl alcohol

Polyoxy 40 stearate

Liquid paraffin

Propylene glycol

Sodium citrate

Citric acid anhydrous

Water purified

6.2 Incompatibilities

None known.

6.3 Shelf life

2 years.

6.4 Special precautions for storage

Do not store above 25° C.

6.5 Nature and contents of container

60g aluminium tubes with screw cap.

6.6 Special precautions for disposal and other handling

No special instructions for disposal and handling.

7. Marketing authorisation holder

Typharm Limited

Unit 1

39 Mahoney Green



NR13 6JY

8. Marketing authorisation number(s)

PL 00551/0012

9. Date of first authorisation/renewal of the authorisation

Date of first authorisation: 28 February 1999

Date of latest renewal: 05 June 2003

10. Date of revision of the text


Typharm Limited
Company image
Unit 1, 39 Mahoney Green, Rackheath, Norwich, Norfolk, NR13 6JY
+44 (0)1603 722480
+44 (0)1603 263804
Medical Information Direct Line
+44 (0)2037 694160
Medical Information e-mail
[email protected]
Customer Care direct line
+44 (0)1603 722480
Stock Availability
+44 (0)1603 722480